Showing results (61-70 of 126) with videos related to
Sort By:
Pageof 13
Drugs|April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORHervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, et al.Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.British Journal of Haematology|July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growthMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
International staging system for multiple myelomaPhilip R Greipp, Jesus San Miguel, Brian G M Durie, et al.Haematologica|April 16, 2016
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaKatja C Weisel, Meletios A Dimopoulos, Philippe Moreau, et al.The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.Pageof 13